Cannabis Bioscience International Holdings Makes Historic Impact
HOUSTON — Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is excited to announce its selection to participate in crucial DEA hearings regarding the rescheduling of marijuana. Being one of the few bioscience cannabis companies invited, CBIH, represented by CEO Mr. Dante Picazo, will present compelling clinical trial data showcasing the therapeutic benefits of Cannabis sativa L.
A Commitment to Research and Innovation
During the hearings, CBIH aims to demonstrate the safety and efficacy of cannabis compounds in medical science, reinforcing its dedication to developing innovative treatments. The data will also emphasize significant economic opportunities that a potential rescheduling of cannabis could provide for the entire industry.
Engaging Key Stakeholders
Mr. John Jones, Treasurer and Director of CBIH, expressed the importance of this event as a vital forum where various stakeholders—including entrepreneurs, physicians, and patients—can interact directly with regulatory authorities. This engagement is crucial for establishing a well-informed and fair regulatory framework for the cannabis sector.
Financial Impact and Market Growth
From a financial perspective, Charles Tamburello, another Director at CBIH, highlighted how such events enhance the credibility of the medical cannabis market, thereby boosting investor confidence. Reports indicate that the U.S. cannabis market was valued at an impressive $33.6 billion in 2023, with expectations of a compound annual growth rate of 12.1% from 2024 to 2030.
Political Support for Cannabis Rescheduling
In recent communications, President-elect Donald Trump has emphasized the importance of rescheduling marijuana. He believes it will lead to supportive legislation aimed at unlocking marijuana’s medical potential and facilitating safe banking options for cannabis businesses.
Highlighting Therapeutic Innovations
Rosangel Andrades, Director of Research and Development at CBIH, passionately stated, "We are deeply honored to participate in this landmark event, presenting data on cannabinoids' potential to treat severe health conditions such as cancer, epilepsy, and neurodegenerative diseases." This underscored the company's commitment to ongoing research and the development of safe treatments.
The Road Ahead for CBIH
With ten patents submitted, Cannabis Bioscience International Holdings is positioning itself as a key player in advocating for fair regulations that could provide millions with access to innovative medical solutions. The company's participation in the DEA hearings marks a significant milestone toward making cannabinoid-based medicine more accessible to the public.
Frequently Asked Questions
What is the significance of CBIH's participation in the DEA hearings?
CBIH's participation highlights its commitment to demonstrating the therapeutic benefits of cannabis and advocating for fair regulations in the industry.
How might rescheduling marijuana impact the cannabis industry?
Rescheduling marijuana could unlock significant economic opportunities and improve investor confidence, facilitating further research and development.
What therapeutic conditions does CBIH focus on?
CBIH is focused on cannabinoids' potential to treat serious conditions like cancer, epilepsy, and neurodegenerative diseases.
What are the expectations for the U.S. cannabis market in the coming years?
The U.S. cannabis market is projected to grow at a compound annual rate of 12.1% from 2024 to 2030, following its valuation of $33.6 billion in 2023.
Who can I contact for more information about CBIH?
You can contact CBIH at (214) 733-0868 or email ir@cbih.net for more detailed information about their initiatives and progress.
